$NIKI

Niki BioSolutions, Inc. (NIKI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with the previously announced merger transaction, Mr. Ian Huen and Alidad Mireskandari became the CEO and CO

Niki BioSolutions, Inc. filed a request with the SEC to withdraw its Form F-3 registration statement, initially submitted on January 16, 2026. The company is no longer a Foreign Private Issuer and has filed a Form S-3 for a previously described offering. No securities were sold under the withdrawn registration.

Niki BioSolutions, Inc. (APM) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-3.2 3 ea029826201ex3-2.htm FORM OF BYLAWS FOR NIKI BIOSOLUTIONS, INC Exhibit 3.2 BY-LAWS OF NIKI BIOSOLUTIONS, INC. (THE “CORPORATION”) ARTICLE I OFFICES The registered office of Niki Biosolutions, Inc. (the “Corporation”) shall be in the State of Delaware. The Corporation als

Andean Precious Metals Corp. (TSX: APM, OTCQX: ANPMF) reported Q2 2026 production of 25,387 gold equivalent ounces, up 4% year over year, and 52,730 GEOs for the first half, up 15%. San Bartolome drove growth; Golden Queen was below prior quarter. The company deferred silver and gold inventory sales and said it had $204.1M liquid assets at Q1 end. Financial results are due Aug. 11.

Aptorum Group Limited (NASDAQ: APM) and DiamiR Biosciences announced three presentations at the 2026 Alzheimer’s Association International Conference (July 11-15, London and online) featuring DiamiR’s blood-based biomarker work, including APOE genotyping and microRNA markers. Aptorum and DiamiR also reported merger shareholder approval on June 9, 2026, with closing expected before fiscal 2027.

Aptorum Group Limited (Nasdaq: APM) said shareholders approved its proposed all-stock merger with DiamiR Biosciences Corp. at a June 9, 2026 meeting. DiamiR’s shareholders also approved. The companies expect the deal to close before fiscal 2027, pending remaining customary closing conditions.

APM and Synergy One will merge as part of a restructuring. Synergy One CEO Steve Majerus will become APM president pending regulatory clearance, while Aaron Nemec will keep leading Synergy One Lending’s daily operations. The companies say the deal preserves Synergy One’s brand via APM’s DBA model and expands products and infrastructure. APM has 2,900+ employees, 300 branches; Synergy One adds 540 employees, 65 branches.

The article compares small-cap medical stocks Aptorum Group (NASDAQ:APM) and Cardiol Therapeutics (NASDAQ:CRDL). It cites beta values of 0.3 for APM and 0.77 for CRDL, institutional ownership of 3.8% vs 12.5%, and insider ownership of 64.0% vs 5.3%. MarketBeat data shows CRDL consensus target price of $8.50 (upside 553.85%). It also states APM has higher revenue and earnings.

Aptorum Group (NASDAQ: APM) received a Nasdaq notification for non-compliance with the $1 minimum bid price rule. The company has a 180-calendar-day grace period until September 1, 2026, to regain compliance and is exploring options, including a potential reverse stock split. The notification does not immediately impact the trading or listing of APM shares.

$2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrants ...